tocilizumab,elranatamab
pfizer,roche
['toci', 'magnetismm-3', 'mmsm', 'elranatamab']
congress | #ash22
nizar bahlis adds that 56.3% patients experienced any-grade crs with elranatamab in magnetismm-3, mitigated by the step-up priming regimen.
#mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma